Saúde Reprodutiva
Planeamento proativo
Hormonas and contraceção
Saúde ovárica
Reprodução medicamente assistida
Biologia uterina
Fertilidade. Educação e consciencialização
Hormonas and contracepção
Saúde ovárica
Reprodução medicamente assistida
Biologia uterina
Infertilidade masculina
Hormones and contraception
Infertilidade feminina
Hormonas and contracepção
Saúde ovárica
Reproducão medicamente assistida
Biologia uterina
Tecnologias de reprodução assistida
Hormones and contraception
Ovarian Health
Medically assisted reproduction
Uterine Biology
Disfuncão erectil
....
Ovarian Health
Medically assisted reproduction
Uterine Biology
Doenças sexualmente transmissiveis
Herpes genital
VIH
Sifilis
Bacterianas (Chlamidia, gonorreia, tricomoníase)
Reproductive Health
Proactive Planning
Hormones and contraception
Ovarian Health
Medically assisted reproduction
Uterine Biology
Fertility. Education and awareness
Hormones and contraception
Ovarian Health
Medically assisted reproduction
Uterine Biology
Male infertility
Hormones and contraception
Ovarian Health
Medically assisted reproduction
Uterine Biology
Erectile dysfunction
....
Ovarian Health
Medically assisted reproduction
Uterine Biology
Female infertility
Hormones and contraception
Ovarian Health
Medically assisted reproduction
Uterine Biology
Assisted reproductive technologies
Hormones and contraception
Ovarian Health
Medically assisted reproduction
Uterine Biology
Sexually transmitted Infections
Herpes genital
HIV
Syphilis
Bacterial (Chlamydia, gonorrhoeae)
Pre-Exposure Prophylaxis (PrEP) for HIV
Post-Exposure Prophylaxis for chlamydia e syphilis
Syphilis
Most people infected with Treponema pallidum for the first time develop symptoms. People with previous episodes of syphilis are considerably less likely to develop symptoms of syphilis.
Herpes simplex virus-2 (HSV-2)
Nearly all people with antibodies to HSV-2 have never had symptoms of genital herpes.
Bacterial (Chlamydia, gonorrhoeae)
The majority of infections are asymptomatic. In Chlamydia, only 11%-33% infections in men and 6%-17% in women become symptomatic. In gonorrhoeae 45%-85% in men and 14-35% in women are symptomatic.
Pre-Exposure Prophylaxis (PrEP) for HIV
The efficacy and safety of daily PrEP for HIV prevention were established over a decade ago.
PrEP has 97% effectiveness when taken daily or on demand. PrEP implementation has led to a significant reduction in HIV incidence at the population level.
Do you want to know how? Get in touch with us.
Post-Exposure Prophylaxis (PrEP) for chlamydia e syphilis
Post-exposure prophylaxis reduces chlamydia and syphilis risk. Do you want to know how? Get in touch with us.